Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
14.50
-0.73 (-4.79%)
At close: Apr 28, 2026, 4:00 PM EDT
14.52
+0.02 (0.14%)
After-hours: Apr 28, 2026, 6:31 PM EDT
Janux Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Janux Therapeutics stock have an average target of 47, with a low estimate of 12 and a high estimate of 100. The average target predicts an increase of 224.14% from the current stock price of 14.50.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Janux Therapeutics stock from 13 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 6 | 5 | 5 | 5 | 6 |
| Buy | 5 | 4 | 4 | 4 | 4 | 3 |
| Hold | 2 | 2 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 12 | 12 | 12 | 12 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jones Trading | Jones Trading | Strong Buy Maintains $50 → $28 | Strong Buy | Maintains | $50 → $28 | +93.10% | Apr 28, 2026 |
| Barclays | Barclays | Buy → Sell Downgrades $29 → $14 | Buy → Sell | Downgrades | $29 → $14 | -3.45% | Apr 20, 2026 |
| UBS | UBS | Strong Buy → Hold Downgrades $57 → $15 | Strong Buy → Hold | Downgrades | $57 → $15 | +3.45% | Apr 15, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $150 → $100 | Buy | Maintains | $150 → $100 | +589.66% | Feb 27, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $72 → $68 | Strong Buy | Maintains | $72 → $68 | +368.97% | Feb 27, 2026 |
Financial Forecast
Revenue This Year
9.22M
from 10.00M
Decreased by -7.81%
Revenue Next Year
6.68M
from 9.22M
Decreased by -27.50%
EPS This Year
-2.60
from -1.83
EPS Next Year
-3.35
from -2.60
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 60.4M | 36.8M | ||||||
| Avg | 9.2M | 6.7M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 503.7% | 298.6% | ||||||
| Avg | -7.8% | -27.5% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.91 | -1.73 | ||||||
| Avg | -2.60 | -3.35 | ||||||
| Low | -3.22 | -5.84 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.